Filing Details

Accession Number:
0000899243-21-044916
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-11-16 19:57:50
Reporting Period:
2021-11-12
Accepted Time:
2021-11-16 19:57:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1640455 Jounce Therapeutics Inc. JNCE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1180428 J Mark Levin C/O Third Rock Ventures, Llc,
29 Newbury Street, 3Rd Floor
Boston MA 02116
No No Yes No
1192595 I Robert Tepper 29 Newbury Street, 3Rd Floor
Boston MA 02116
No No Yes No
1192603 P Kevin Starr 29 Newbury Street, 3Rd Floor
Boston MA 02116
No No Yes No
1569705 Third Rock Ventures Iii, L.p. C/O Third Rock Ventures, Llc,
29 Newbury Street, 3Rd Floor
Boston MA 02116
No No Yes No
1637299 Trv Gp Iii, Llc 29 Newbury Street, 3Rd Floor
Boston MA 02116
No No Yes No
1637300 Third Rock Ventures Gp Iii, L.p. 29 Newbury Street, 3Rd Floor
Boston MA 02116
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-11-12 1,900,000 $8.38 1,148,780 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 2,697,829 Indirect See footnote
Common Stock 284,344 Indirect See footnote
Common Stock 283,850 Indirect See footnote
Common Stock 283,858 Indirect See footnote
Footnotes
  1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.30 to $8.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  2. These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
  3. These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Levin, Starr and Tepper. Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
  4. The shares are directly held by Levin.
  5. The shares are directly held by Starr.
  6. The shares are directly held by Tepper.